Dopamine agonists in schizophrenia: a review

@article{Benkert1995DopamineAI,
  title={Dopamine agonists in schizophrenia: a review},
  author={Otto Benkert and Florian M{\"u}ller-Siecheneder and Hermann Wetzel},
  journal={European Neuropsychopharmacology},
  year={1995},
  volume={5},
  pages={43-53}
}

Dopamine in schizophrenia.

The ongoing and future work on the precise role of DA in schizophrenia should focus on first-episode/admission neuroleptic-naive schizophrenic patients, as such studies represent the best opportunity of finding out specific changes in the dopaminergic pathways and relating them in a meaningful way to various dimensions of psychopathology seen in schizophrenia patients.

Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.

Strategies for obtaining ideal effective antipsychotics with reduced side effects are considered in this short review with respect to the intrinsic efficacies and affinities of the partial agonists, based on thepartial agonist concept.

Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review.

Schizophrenia has been historically characterized by the presence of positive symptomatology, however, decades of research highlight the importance of cognitive deficits in this disorder. At present,

The role of dopamine in the pathophysiology and treatment of apathy.

Neurobiological Background for the Development of New Drugs in Schizophrenia

Research in the antipsychotics field has developed also by exploring pathways that are beyond the spectrum of clozapine, and among the most promising mechanisms are those based on the glutamatergic hypothesis of schizophrenia.

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties

Compounds possessing “balanced” 5- HT1A receptor agonism and D2 antagonism and, in some cases, combined with other beneficial properties, such as 5-HT2A receptor antagonism, are efficacious in a broad range of rodent pharmacological models yet have a lower propensity to elicit EPS or metabolic dysfunction.

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

An update and critical review of the pharmacology and clinical profiles of current antipsychotic drugs and drugs acting on novel targets with potential to be therapeutic agents in the future is provided.

Pharmacology of "atypicality" of antipsychotic drugs: status and perspectives

Summary "Atypical" antipsychotics are antagonists at serotonin 5-HT2A and dopamine d2 receptors. However, their effects on negative symptoms and cognitive deficits remain modest and they disrupt

A meta-analysis of the response to chronic l-dopa in patients with schizophrenia: therapeutic and heuristic implications

In patients already on antipsychotic drugs, the addition of l-dopa can be beneficial, and Dopamine agonists merit further consideration as adjuncts to antipsychotics drugs in the treatment of schizophrenia.
...

References

SHOWING 1-10 OF 55 REFERENCES

Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression.

Current evidence from pilot studies suggests that dopamine autoreceptor agonists like roxindole may produce a minor to moderate improvement of symptoms like affective flattening, depressed mood, alogia, and avolition, possibly by stimulation of supersensitive postsynaptic dopamine receptors.

Dopamine autoreceptor agonists in the treatment of schizophrenic disorders

  • H. WetzelO. Benkert
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 1993

Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia.

Partial dopamine agonists showing high affinity but low efficacy at D2 receptors can act as dopaminergic "buffers," reducing dopaminergic activity when it is excessive, and promoting it when reduced.

Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.

A clinical investigation of EMD 49980 in affective disorders and in schizophrenia with depression or anergia should be performed, in view of the only moderate antipsychotic efficacy in acute schizophrenia.

B-HT920 - A Novel Dopamine Autoreceptor Agonist in the Treatment of Patients with Schizophrenia

In an open clinical trial the azepine derivative B-HT 920 was administered to patients with schizophrenia, paranoid type (according to ICD-9 and DSM-III criteria), in order to examine whether

Clinical Effects of Apomorphine in Schizophrenia

A placebo-controlled study of acute and chronic schizophrenics in which videotaped interviews were blindly rated found no specific therapeutic effect was demonstrated for apomorphine other than a reduction in anxiety in acute schizophrenics.

Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies.

  • H. Meltzer
  • Biology, Psychology
    Schizophrenia bulletin
  • 1980
Preclinical and clinical studies suggest that administration of low doses of conventional dopamine agonists such as apomorphine can inhibit the activity of some dopaminergic neurons and be of therapeutic use in the treatment of excited psychotic states and a variety of abnormal movement disorders.

Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.

Results indicate that an active though nonsedating dose of apomorphine does not ameliorate symptoms of schizophrenia or tardive dyskinesia.

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

The cloning of a gene that encodes a dopamine receptor gene that has high homology to the human dopamine D2 and D3 receptor genes is reported, which suggests the existence of other types of dopamine receptors which are more sensitive to clozapine.
...